"10.1371_journal.pone.0071193","plos one","2013-08-12T00:00:00Z","Martin Ungerer; Zhongmin Li; Christine Baumgartner; Silvia Goebel; Jasmin Vogelmann; Hans-Peter Holthoff; Meinrad Gawaz; Götz Münch","advanceCOR GmbH (formerly, Procorde GmbH), Martinsried, Germany; Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard Karls Universität Tübingen, Tübingen, Germany","Conceived and designed the experiments: MU GM. Performed the experiments: ZL CB SG HPH. Analyzed the data: JV MU. Contributed reagents/materials/analysis tools: MG. Wrote the paper: MU.","Authors MU, ZL, SG, JV, HPH and GM are employed by, or hold shares of the biotech company advanceCOR GmbH - this company funded this study. MG is a co-founder of AdvanceCOR, owns shares of AdvanceCOR and is Professor at the Cardiology Department of the University of Tübingen. He further received honoraria payments from Lilly, Bristol-Myers Squibb and Bayer-Schering and is also consultant for Bayer-Schering. CB was an employee of the predecessor company, ProCorde GmbH, at the time of the study. Advancecor holds patents on and develops GPVI-Fc as a product for the treatment of patients with vascular diseases. There are no marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Martin Ungerer","MU",8,TRUE,2,4,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
